MY139720A - Micronized crystalline tiotropium bromide - Google Patents

Micronized crystalline tiotropium bromide

Info

Publication number
MY139720A
MY139720A MYPI20030947A MYPI20030947A MY139720A MY 139720 A MY139720 A MY 139720A MY PI20030947 A MYPI20030947 A MY PI20030947A MY PI20030947 A MYPI20030947 A MY PI20030947A MY 139720 A MY139720 A MY 139720A
Authority
MY
Malaysia
Prior art keywords
tiotropium bromide
crystalline tiotropium
micronized crystalline
preparing
pharmaceutical composition
Prior art date
Application number
MYPI20030947A
Inventor
Bender Dr Helmut
Graebner Dr Hagen
Schindler Konrad
Trunk Dr Michael
Walz Dr Michael
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27797948&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY139720(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of MY139720A publication Critical patent/MY139720A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Catalysts (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Glass Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Hybrid Cells (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

THE INVENTION RELATES TO A CRYSTALLINE MICRONISATE OF (1, 2, 4, 5, 7)-7-[(HYDROXYDI-2-THEINYLACETYL)-OXY]-9,9-DIMENTHYL-3-OXA-9-AZONIATRICYCLO[3.3.1.02,4] NONANE-BROMIDE, PROCESSES FOR PREPARING IT AND ITS USE FOR PREPARING A PHARMACEUTICAL COMPOSITION, PARTICULARLY FOR PREPARING A PHARMACEUTICAL COMPOSITION WITH AN ANTICHOLINERGIC ACTIVITY.
MYPI20030947A 2002-03-20 2003-03-18 Micronized crystalline tiotropium bromide MY139720A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10212264A DE10212264A1 (en) 2002-03-20 2002-03-20 Crystalline micronisate, process for its preparation and its use for the manufacture of a medicament

Publications (1)

Publication Number Publication Date
MY139720A true MY139720A (en) 2009-10-30

Family

ID=27797948

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20030947A MY139720A (en) 2002-03-20 2003-03-18 Micronized crystalline tiotropium bromide

Country Status (37)

Country Link
EP (3) EP1785422B1 (en)
JP (1) JP4331619B2 (en)
KR (2) KR101021430B1 (en)
CN (2) CN101220025A (en)
AR (1) AR039017A1 (en)
AT (1) ATE369365T1 (en)
AU (1) AU2003212327B2 (en)
BR (1) BRPI0308513B8 (en)
CA (1) CA2479652C (en)
CO (1) CO5611105A2 (en)
CY (2) CY1106923T1 (en)
DE (2) DE10212264A1 (en)
DK (2) DK1785422T3 (en)
EA (1) EA007064B1 (en)
EC (1) ECSP045310A (en)
ES (2) ES2291619T5 (en)
HK (1) HK1078871A1 (en)
HR (1) HRP20040855B1 (en)
HU (1) HUE031876T2 (en)
IL (2) IL163841A0 (en)
LT (1) LT1785422T (en)
ME (1) ME02764B (en)
MX (1) MXPA04009056A (en)
MY (1) MY139720A (en)
NO (2) NO346754B1 (en)
NZ (1) NZ535808A (en)
PE (1) PE20030838A1 (en)
PL (1) PL220730B1 (en)
PT (2) PT1785422T (en)
RS (1) RS57551B1 (en)
SA (1) SA03240098B1 (en)
SI (1) SI1487832T2 (en)
TW (1) TWI345975B (en)
UA (1) UA78295C2 (en)
UY (1) UY27725A1 (en)
WO (1) WO2003078429A1 (en)
ZA (1) ZA200405636B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
PT1682541E (en) 2003-11-03 2010-04-14 Boehringer Ingelheim Int Method for producing tiotropium salts
UY28589A1 (en) 2003-11-03 2005-06-30 Boehringer Ingelheim Int NEW TIOTROPE SALTS, PROCEDURES FOR PREPARATION, AS WELL AS MEDICINAL FORMULATIONS CONTAINING THEM
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
DE102004024451A1 (en) 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder formulations for inhalation containing enantiomerically pure beta agonists
ES2393794T3 (en) 2005-05-02 2012-12-28 Boehringer Ingelheim International Gmbh New crystalline forms of tiotropium bromide
CN101203513A (en) * 2005-05-02 2008-06-18 贝林格尔·英格海姆国际有限公司 Novel crystalline forms of tiotropium bromide
MX2008001976A (en) 2005-08-15 2008-03-25 Boehringer Ingelheim Int Method for producing betamimetics.
US20070086957A1 (en) * 2005-10-10 2007-04-19 Thierry Bouyssou Combination of medicaments for the treatment of respiratory diseases
DE102005059602A1 (en) 2005-12-14 2007-06-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Micronization process
US9108962B2 (en) 2005-12-19 2015-08-18 Sicor, Inc. Forms of tiotropium bromide and processes for preparation thereof
US8163913B2 (en) * 2005-12-19 2012-04-24 Sicor Inc. Forms of tiotropium bromide and processes for preparation thereof
CN100999521B (en) * 2006-01-13 2010-12-08 江苏正大天晴药业股份有限公司 Crystal anti-choline medicine thiatropic bromoammonium
GB0716026D0 (en) 2007-08-16 2007-09-26 Norton Healthcare Ltd An inhalable medicament
WO2011093815A2 (en) * 2010-01-29 2011-08-04 Mahmut Bilgic Pharmaceutical compositions comprising formoterol and mometasone
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
PT106142B (en) * 2012-02-10 2014-07-18 Hovione Farmaci Ncia S A PROCESS FOR THE PREPARATION OF TIOTROPE BROMIDE
WO2014007768A1 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dry powder inhaler compositions comprising long acting muscorinic antagonists
EP2705838A1 (en) * 2012-09-06 2014-03-12 Xspray Microparticles Ab Tiotropium preparations
EP2897955B1 (en) * 2012-09-11 2019-11-06 Bilgic, Mahmut New tiotropium bromide crystalline form
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
TN2017000077A1 (en) 2014-09-09 2018-07-04 Vectura Ltd Formulation comprising glycopyrrolate, method and apparatus
PT3159277T (en) * 2015-10-23 2019-09-11 Arven Ilac Sanayi Ve Ticaret As Blister for inhalable formulation of tiotropium bromide
EP3159278A1 (en) * 2015-10-23 2017-04-26 Arven Ilac Sanayi Ve Ticaret A.S. Blister for tiotropium bromide inhalable formulation
CN115737610B (en) * 2021-12-13 2024-02-27 苏州欧米尼医药有限公司 Air flow crushing method for tiotropium bromide inhalation powder fog agent and active ingredient thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
FR2585563B1 (en) 1985-07-30 1993-11-12 Glaxo Group Ltd DEVICE FOR ADMINISTERING MEDICINES TO PATIENTS
DE3931041C2 (en) * 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Esters of thienyl carboxylic acids with amino alcohols, their quaternization products, processes for their preparation and medicaments containing them
US5610163A (en) 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
SE9302777D0 (en) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
DE4318455A1 (en) 1993-06-03 1994-12-08 Boehringer Ingelheim Kg Capsule holder
DE19515625C2 (en) * 1995-04-28 1998-02-19 Boehringer Ingelheim Kg Process for the production of enantiomerically pure tropic acid esters
FR2779347A1 (en) * 1998-06-05 1999-12-03 Arlette Guerry Micronization of medicaments to improve homogeneity and bioavailability of active compound
US6475467B1 (en) 1998-08-04 2002-11-05 Jago Research Ag Medicinal aerosol formulations
PT1283036E (en) * 1998-11-13 2008-03-06 Jagotec Ag Multidosis dry powder inhaler with powder reservoir
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
DE19921693A1 (en) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Pharmaceutical composition for treating respiratory disorders, e.g. asthma, comprises combination of anticholinergic and beta-mimetic agents having synergistic bronchospasmolytic activity and reduced side-effects
EP1171155A2 (en) † 1999-04-23 2002-01-16 Research Corporation Technologies Therapeutic compositions and methods for enhancing angiogenesis
EP1238661A1 (en) 1999-10-12 2002-09-11 Kaken Pharmaceutical Co., Ltd. Powdery inhalational preparations and process for producing the same
CN1210017C (en) 2000-10-12 2005-07-13 贝林格尔英格海姆法玛两合公司 Novel tiotropiumonium-containing inhalation powder
OA12403A (en) 2000-10-12 2006-04-18 Boehringer Ingelheim Pharma Crystalline monohydrate, method for producing the same and the use thereof in the production of a medicament.
DE10126924A1 (en) 2001-06-01 2002-12-05 Boehringer Ingelheim Pharma Inhalation capsule contains powdered mixture of tiotropium and auxiliary, for treating asthma or chronic obstructive pulmonary disease, having capsule material of low moisture content to improve stability
BR0210537A (en) 2001-06-22 2004-06-22 Boehringer Ingelheim Pharma Crystalline anticholinergic, process for its preparation and its application for the preparation of a medicine
US7309707B2 (en) 2002-03-20 2007-12-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
AU2003276525A1 (en) 2002-11-15 2004-06-15 Orchid Chemicals And Pharmaceuticals Ltd Novel amorphous hydrate of a cephalosporin antibiotic
DE102005059602A1 (en) 2005-12-14 2007-06-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Micronization process
CN102127069A (en) 2010-01-20 2011-07-20 鲁南制药集团股份有限公司 Tiotropium bromide crystal

Also Published As

Publication number Publication date
CY1118855T1 (en) 2018-01-10
EP1487832B1 (en) 2007-08-08
PT1785422T (en) 2017-02-17
CA2479652C (en) 2012-07-10
KR20050008662A (en) 2005-01-21
JP4331619B2 (en) 2009-09-16
NZ535808A (en) 2005-09-30
EP1487832B2 (en) 2018-08-29
ZA200405636B (en) 2006-01-25
CN101220025A (en) 2008-07-16
BRPI0308513B1 (en) 2016-04-19
HUE031876T2 (en) 2017-08-28
PL371799A1 (en) 2005-06-27
SI1487832T1 (en) 2007-12-31
DK1785422T3 (en) 2017-02-27
DE50307883D1 (en) 2007-09-20
EP1785422A8 (en) 2010-06-23
JP2005526776A (en) 2005-09-08
HK1078871A1 (en) 2006-03-24
ECSP045310A (en) 2004-10-26
KR101094091B1 (en) 2011-12-15
KR101021430B1 (en) 2011-03-15
ATE369365T1 (en) 2007-08-15
PE20030838A1 (en) 2003-11-21
EA007064B1 (en) 2006-06-30
UA78295C2 (en) 2007-03-15
DE10212264A1 (en) 2003-10-02
SA03240098B1 (en) 2008-03-24
NO344427B1 (en) 2019-12-02
PL220730B1 (en) 2015-12-31
RS57551B1 (en) 2018-10-31
PT1487832E (en) 2007-08-27
LT1785422T (en) 2017-02-10
UY27725A1 (en) 2003-10-31
CA2479652A1 (en) 2003-09-25
ME02764B (en) 2011-05-10
EP1785422A1 (en) 2007-05-16
NO20044003L (en) 2004-10-14
AU2003212327B2 (en) 2009-02-05
CO5611105A2 (en) 2006-02-28
AR039017A1 (en) 2005-02-02
IL163841A (en) 2015-10-29
IL163841A0 (en) 2005-12-18
TWI345975B (en) 2011-08-01
AU2003212327A1 (en) 2003-09-29
DK1487832T3 (en) 2007-11-05
BR0308513A (en) 2005-01-04
NO346754B1 (en) 2022-12-12
MXPA04009056A (en) 2005-01-25
CN1642952A (en) 2005-07-20
DK1487832T4 (en) 2018-12-10
CY1106923T1 (en) 2012-09-26
WO2003078429A1 (en) 2003-09-25
ES2291619T5 (en) 2018-12-07
EA200401142A1 (en) 2005-04-28
EP1487832A1 (en) 2004-12-22
KR20100135983A (en) 2010-12-27
ES2291619T3 (en) 2008-03-01
SI1487832T2 (en) 2018-11-30
EP3053921A1 (en) 2016-08-10
HRP20040855B1 (en) 2012-11-30
EP1487832B9 (en) 2019-01-23
HRP20040855A2 (en) 2005-06-30
TW200305421A (en) 2003-11-01
CN100368410C (en) 2008-02-13
EP1785422B1 (en) 2016-11-16
MEP46708A (en) 2011-02-10
ES2615460T3 (en) 2017-06-07
NO20190824A1 (en) 2004-10-14
BRPI0308513B8 (en) 2021-05-25

Similar Documents

Publication Publication Date Title
MY139720A (en) Micronized crystalline tiotropium bromide
MY122779A (en) Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition.
BR0114584A (en) Crystalline monohydrate, processes for its preparation and its application for the preparation of a medicament
IL174208A0 (en) Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation
MY130803A (en) New quinuclidine amide derivatives
NO20055766L (en) Positive modulators of nicotine acetylcholine receptors
MXPA02012712A (en) N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity.
WO2004000840A3 (en) Quinuclidine derivatives and pharmaceutical compositions containing the same
TW200630100A (en) Formulations of [1,4]diazepino[6,7,1- ij]quinoline derivatives
AU2002354054A1 (en) Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient
AU2003239389A1 (en) Opioid receptor antagonists
MXPA04009162A (en) Piperidine or 8-aza-bicyclo[3.2.1]oct-3-yl derivatives useful as modulators of chemokine receptor activity (especially ccr5).
MY148318A (en) Crystalline forms of an 8-azabicyclo [3.2.1] octane compound
GEP20105095B (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
AU2002365288A1 (en) Tropane derivatives having dopamine reuptake inhibitor activity for the treatment of ischemic diseases
HUP0103912A3 (en) Substituted alkylpyridazinone derivatives, process for their preparation, their use for the preparation of pharmaceutical compositions with anxiolytic activity
AU2002335304A1 (en) The use of berberine as insulin sensitizer
AU2003298117A1 (en) 2-substituted triazolopyrimidines, methods and intermediate products for the production thereof, the use of the same for controlling pathogenic fungi, and agents containing said compounds
WO2004024682A3 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity.
AU2003252361A1 (en) Alkynyl-substituted azasugar derivative and drug containing the same as the active ingredient
MY141461A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
UA84714C2 (en) Normal;heading 1;heading 2;IMIDAZOPYRIDINE SUBSTITUTED TROPANE DERIVATIVES WITH CCR5 RECEPTOR ANTAGONIST ACTIVITY FOR THE TREATMENT OF HIV AND INFLAMMATION
AU2003208064A1 (en) Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient